Literature DB >> 10656438

Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma.

S A Rempel1, S Dudas, S Ge, J A Gutiérrez.   

Abstract

Glioblastoma multiforme (GBM) tumors display extensive histomorphological heterogeneity, with great variability in the extent of invasiveness, angiogenesis, and necrosis. The identification of genes associated with these phenotypes should further the molecular characterization, permitting better definition of glioma subsets that may ultimately lead to better treatment strategies. Therefore, we performed a differential mRNA display analysis comparing six GBM-derived primary cell cultures from patients having tumors with varied histomorphological features. We identified stromal cell-derived factor 1 (SDF1) as a gene with varied expression. SDF1 (cytokine) and CXC chemokine receptor 4 (CXCR4) interactions are implicated in modulating cell migration. They are also implicated in modulating the immune response in AIDS patients by macrophage-mediated T-cell apoptosis. GBM patients also fail to mount an immune response, although their tumors are seemingly exposed to immune cells in regions of angiogenesis, where the blood-brain barrier is absent, or in areas of necrosis. To determine whether the expression and localization of SDF1 and CXCR4 are consistent with such a role in these brain tumors, immunohistochemical analyses of these proteins were performed on normal brain and astrocytomas (grades II-IV). In normal brain tissue, low levels of SDF1 (0.5+) were observed in astrocytic processes, in neurons, and in the occasional phagocytic cells around vessels. CXCR4 expression was negative in brain tissue but was observed in phagocytic cells within the vessel lumen. In tumors, SDF1 and CXCR4 expression was colocalized when both were expressed, and SDF1 and CXCR4 expression increased with increasing tumor grade (from 0.5+ to 6+). Additionally, CXCR4 was expressed in neovessel endothelial cells. The proteins were expressed in regions of angiogenesis and degenerative, necrotic, and microcystic changes. Those tumors displaying greater amounts of these features had greater staining intensity of the proteins. The expression of SDF1 and CXCR4 did not colocalize with the proliferation marker MIB-1. Thus, our data suggest that SDF1 and CXCR4 expressions: (a) increase with increasing grade; (b) colocalize to regions within these tumors where their interaction may contribute to angiogenesis and/or modulation of the immune response; and (c) may serve to characterize subsets of GBMs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10656438

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  122 in total

Review 1.  Chemokines and glial cells: a complex network in the central nervous system.

Authors:  Elena Ambrosini; Francesca Aloisi
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

Review 2.  Fugetaxis: active movement of leukocytes away from a chemokinetic agent.

Authors:  Fabrizio Vianello; Ivona T Olszak; Mark C Poznansky
Journal:  J Mol Med (Berl)       Date:  2005-09-03       Impact factor: 4.599

3.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Authors:  Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

Review 4.  CXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targeting.

Authors:  Hyo Jin Lee; Ik-Chan Song; Hwan-Jung Yun; Deog-Yeon Jo; Samyong Kim
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

5.  A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.

Authors:  Joshua B Rubin; Andrew L Kung; Robyn S Klein; Jennifer A Chan; YanPing Sun; Karl Schmidt; Mark W Kieran; Andrew D Luster; Rosalind A Segal
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

6.  Distinct modifications in Kv2.1 channel via chemokine receptor CXCR4 regulate neuronal survival-death dynamics.

Authors:  Andrew J Shepherd; Lipin Loo; Raeesa P Gupte; Aaron D Mickle; Durga P Mohapatra
Journal:  J Neurosci       Date:  2012-12-05       Impact factor: 6.167

Review 7.  Chemokine signaling in cancer: one hump or two?

Authors:  Joshua B Rubin
Journal:  Semin Cancer Biol       Date:  2008-10-17       Impact factor: 15.707

Review 8.  The role of the CXCR4 cell surface chemokine receptor in glioma biology.

Authors:  Moneeb Ehtesham; Elliot Min; Neil M Issar; Rebecca A Kasl; Imad S Khan; Reid C Thompson
Journal:  J Neurooncol       Date:  2013-03-14       Impact factor: 4.130

9.  Experimental and computational analyses reveal dynamics of tumor vessel cooption and optimal treatment strategies.

Authors:  Chrysovalantis Voutouri; Nathaniel D Kirkpatrick; Euiheon Chung; Fotios Mpekris; James W Baish; Lance L Munn; Dai Fukumura; Triantafyllos Stylianopoulos; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-30       Impact factor: 11.205

10.  Effect of bexarotene on differentiation of glioblastoma multiforme compared with ATRA.

Authors:  Jin-Chul Heo; Tae-Hoon Jung; Sungjin Lee; Hyun Young Kim; Gildon Choi; Myungeun Jung; Daeyoung Jung; Heung Kyoung Lee; Jung-Ok Lee; Ji-Hwan Park; Daehee Hwang; Ho Jun Seol; Heeyeong Cho
Journal:  Clin Exp Metastasis       Date:  2016-03-08       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.